Mayne Pharma Announces Scheme Implementation Deed with Gedeon Richter
Key points
- Acquisition price for Mayne Pharma Shares of A$6.40 per share in cash
- Scheme Consideration values Mayne Pharma's equity at approximately A$604 million
- The Mayne Pharma Board unanimously recommends voting in favor of the Scheme
Full summary
Mayne Pharma Group Limited (ASX: MYX) has entered into a Scheme Implementation Deed (SID) with Gedeon Richter Plc. for the acquisition of 100% of Mayne Pharma's shares at A$6.40 per share, totaling approximately A$604 million. The Scheme Consideration represents a 99.4% premium to Mayne Pharma's pre-announcement share price. The transaction is subject to regulatory approvals, shareholder approval, and the completion of the sale of Mayne Pharma's International business to Evaris Pharma. The Mayne Pharma Board unanimously recommends shareholders vote in favor of the Scheme, in the absence of a Superior Proposal and subject to the Independent Expert concluding that the Scheme is in the best interests of Mayne Pharma shareholders.
Summary generated by a large language model. Please interpret with care.